Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. - Wikidata - awgldk - TriplyDB

Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q34382683

about

Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease MR Elastography of Liver Disease: State of the Art.Liver fibrosis markers of nonalcoholic steatohepatitis.Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.Can NASH be diagnosed, graded, and staged noninvasively?Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis.Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia.Nonalcoholic fatty liver disease: Diagnostic biomarkers.Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.New clinical score to diagnose nonalcoholic steatohepatitis in obese patients.Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.Diagnosis and evaluation of nonalcoholic fatty liver disease.Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease.Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr.ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease.Effects of one-time and two-time intra-articular injection of hyaluronic acid sodium salt after joint surgery in dogs.Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.Is there a place for serum laminin determination in patients with liver disease and cancer?Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection Assessment of fibrosis in chronic liver diseases.Implication of normal liver enzymes in liver disease.Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.Nonalcoholic fatty liver disease in children living in the obeseogenic society.

P2860

Q24644869-7006D7DF-4E2E-4299-A92F-3E70C44854CF Q26752723-BC6D94F1-1B10-487E-8C5E-9B58413173BE Q26800894-D5A16DA3-D3CB-41A2-AAE7-2FC56B5835F4 Q26828855-460FEFCD-5486-46BF-A61D-E4D317EF3B74 Q27021754-D8EA3A54-0C75-4365-A8EE-CD90284C6373 Q27496667-8203CBB7-8790-44B6-8074-C2FD3B599F78 Q30403258-41EF48CB-0EB3-4E21-8920-953FADE009FD Q30407625-E05F09B5-CFA5-4DAC-9503-2BB2E2D2412D Q30435948-E72D3AC9-1781-4629-955E-3ED4B36B2530 Q30451362-25F2A785-7291-40F7-9588-35B8A2CA3009 Q30464608-613AE13E-879C-4C7D-B8A8-AE66DA348F9A Q30467234-F9504A7C-521D-442B-A281-A1B8AA7C89E2 Q33263279-72AD72CA-747D-46D7-9482-67197493926A Q33384921-4FF23A9B-7B29-412C-BDBC-4C1050994C1D Q33491250-A18B3A05-333D-4109-8E6E-F58B1BC92199 Q33612450-D46BD459-1D0E-49F1-8F10-8D6984145A40 Q33706254-3D0849D4-5B7A-4DE6-9FA1-9F23ACE9A99C Q33866383-A6D14923-4E69-41A9-8C27-A5C346581ADB Q33886918-1CE362B3-AB1E-45FA-9C2D-91472C45AC90 Q34207845-EBA898A1-EAD4-4AAD-93EE-6103523763B0 Q34256132-14DF1953-E944-4205-87A7-278EE50ADCC9 Q34662500-E3D784AA-D983-49EB-9B08-06123B274774 Q34812618-0B8C0814-605B-4208-B0A8-869C82C17716 Q34830398-464AEA0C-40FB-4675-9FCA-8A32F7072F96 Q35233535-988885BC-FCA9-40D0-A981-01CA5A08A3AB Q35495753-6392E02F-6B4E-43B9-A61A-B05F30D2E1D4 Q35768951-2A0E2D5B-F5D8-4C95-BBF0-C26545FCCC6C Q35769146-2962F454-EBE8-47C4-8E97-3B006FD2146F Q35946481-B5C20DD2-419E-497A-A93F-A9C42071D6A0 Q36280695-C9E62AB2-0627-48FC-9939-F73CF759ACA3 Q36656294-9379262B-EEB9-4766-9F17-74681D4D41FC Q36958949-03FE6A65-1CF8-4740-90A2-2DC12EC8A6C3 Q37078109-192BD16B-04D7-4CC2-A1F0-0AB1BEC21F29 Q37192623-F7C677D6-C82B-4FC3-8801-0BC1647F2AD0 Q37205152-FDB61573-14FD-4433-90A4-59A3EE2A5A42 Q37222778-AEC7A5C5-8CBC-43F8-A3AE-06F5F9D10B6F Q37399469-0FFFD263-E762-41DA-B5C1-5F66186155C5 Q37572860-4E85D1C3-24A8-458C-A00B-CC7362555185 Q37613375-17866627-4882-464C-AF73-A8A73E646F1E Q37632281-281DA974-654A-466D-9D05-310004123C66

P2860

Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q34382683

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@ast

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@en

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@nl

type

label

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@ast

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@en

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@nl

prefLabel

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@ast

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@en

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@nl

P1433

Q34382683-E555C840-F4DC-40D4-855A-17DE6243CA15

P1476

Q34382683-B9E84D29-F5CF-4F31-B948-05976309F157

P2093

Q34382683-16A9732F-F231-46AA-BAF4-5113E2174AA0

Q34382683-2BD71E84-7E61-4C81-B29C-8696C9BDF1A4

Q34382683-568B79AF-07C5-4370-8D1E-180568CEB7A8

Q34382683-64DDE974-3BEA-4C70-8743-B9BE294B98B0

Q34382683-6EA04C59-B417-4E2C-BF2E-A8643ACE4C0C

Q34382683-8507BE78-1A93-4EEF-9CE7-1779DA77B927

Q34382683-A1DD232E-1805-4A4D-B15A-F010E2F218B9

Q34382683-A1E57010-4EF9-46CF-BA30-31688FEB55F0

Q34382683-C8CE46A6-46E2-4BB4-86DB-44D6478A8474

Q34382683-CC4C2219-9902-44E1-9E59-4BB3EAA4ABF1

P2860

Q34382683-03E02CD7-8804-4970-A0A3-CE8934681086

Q34382683-11635A53-AC2D-475F-A1A3-5D4AD2367239

Q34382683-1AC564B9-8232-45DF-992A-9FCB1C30CE70

Q34382683-25D685BA-D862-4477-B1C7-1AC3FEDA187A

Q34382683-3047EBA4-8756-4A34-844F-AC8ADA99EDD1

Q34382683-3175E3C2-08DE-40C4-A825-FBAC67C85A1F

Q34382683-39EB21C0-CB9D-490A-851E-30285D1D7F59

Q34382683-450232DC-879F-44C1-9739-2AAB2D3C8A97

Q34382683-464FCE43-E58A-4449-A925-6436EC1253D2

Q34382683-559A787E-F55F-4813-B737-5A1E9A496748

P304

Q34382683-2535B906-1F69-410D-8AAB-C6552B56F188

P31

Q34382683-0E31550D-9906-4F67-8C8D-4C70749E760A

P356

Q34382683-93E07597-5B70-430B-93E6-2400271E5D05

P407

Q34382683-4065B087-E3C8-48D2-BE90-664667E787E3

P433

Q34382683-130CA2D1-E3A5-4FBB-8CDC-3C7DF0ADB6A4

P478

Q34382683-C0C6D621-616A-4C4B-8710-768DC5128E3F

P577

Q34382683-4CEBC558-C3BE-4107-9491-C3F27C185703

P5875

Q34382683-E5A848BD-503A-4BA2-8DB4-EEA70CF4273B

P698

Q34382683-216B8074-17CA-43C4-B0F5-3760131BAE6C

P921

Q34382683-A8ECCEDA-7FBE-44BB-A946-3872497270AF

P932

Q34382683-090FD2B0-9D08-4353-820A-537437367486

P356

P1433

World Journal of Gastroenterology

P1476

Clinical usefulness of biochem ...... alcoholic fatty liver disease.

@en

P2093

Akiyo Toyama

http://www.w3.org/2001/XMLSchema#string

Atsushi Saito

http://www.w3.org/2001/XMLSchema#string

Fukunori Kinjo

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sakugawa

http://www.w3.org/2001/XMLSchema#string

Joji Shiroma

http://www.w3.org/2001/XMLSchema#string

Kasen Kobashigawa

http://www.w3.org/2001/XMLSchema#string

Satoru Miyagi

http://www.w3.org/2001/XMLSchema#string

Tatsuji Maeshiro

http://www.w3.org/2001/XMLSchema#string

Tomofumi Nakayoshi

http://www.w3.org/2001/XMLSchema#string

Tomokuni Nakayoshi

http://www.w3.org/2001/XMLSchema#string

P2860

Liver fibrosis in overweight patients

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Obesity as a medical problem

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Clinical features and natural history of nonalcoholic steatosis syndromes.

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

Nonalcoholic steatohepatitis: what we know in the new millennium.

P304

255-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V11.I2.255

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8098205

http://www.w3.org/2001/XMLSchema#string

P698

15633226

http://www.w3.org/2001/XMLSchema#string

P921

P932

4205412

http://www.w3.org/2001/XMLSchema#string